MANNKIND CORP Convertible Debt
MANNKIND CORP (MNKD) had Convertible Debt of $9.96 million as of 2019-09-30, per its 10-Q filed 2019-11-08.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:ConvertibleDebt · last filed 2019-11-08
- 2019-09-30: Convertible Debt $9.96M.
- 2018-12-31: Convertible Debt $19.10M.
| Period end | Convertible Debt |
|---|---|
| 2019-09-30 | $9.96M 10-Q · filed 2019-11-08 |
| 2018-12-31 | $19.10M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |